Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Patricia Kalafut"'
Autor:
Rami S. Komrokji, Michael R. Grunwald, Evan Braunstein, J.E. Hamer-Maansson, Patricia Kalafut, John Mascarenhas
Publikováno v:
Blood. 140:6832-6834
Autor:
Aaron T. Gerds, Roger M. Lyons, Philomena Colucci, Patricia Kalafut, Dilan Paranagama, Srdan Verstovsek
Publikováno v:
Clinical lymphoma, myelomaleukemia. 22(7)
Clinical characteristics and treatment patterns of patients with lower-risk myelofibrosis (MF) are not well described. This analysis from the MOST (NCT02953704) assessed the demographic and clinical characteristics and treatment patterns of patients
Autor:
Srdan Verstovsek, Patricia Kalafut, Robyn M. Scherber, Rami S. Komrokji, Haobo Ren, Brady L. Stein
Publikováno v:
Blood. 136:49-51
Background: Myelofibrosis (MF) is a chronic Philadelphia chromosome-negative myeloproliferative neoplasm (MPN) characterized by extramedullary hematopoiesis, bone marrow fibrosis, splenomegaly, constitutional symptoms, and diminished quality of life.
Autor:
Roger M, Lyons, David, Lessen, Salman, Fazal, Robyn, Scherber, Patricia, Kalafut, Haobo, Ren, Ellen, Ritchie
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S329
Myelofibrosis and Essential Thrombocythemia Observational STudy (MOST) (NCT02953704) is an ongoing observational study in essential thrombocythemia (ET) or myelofibrosis (MF) patients enrolled in academic (AC) and community (CC) centers throughout th
Autor:
Roger M. Lyons, Patricia Kalafut, Haobo Ren, David S. Lessen, Ellen K. Ritchie, Robyn M. Scherber, Salman Fazal
Publikováno v:
Blood. 138:1497-1497
Background: The Myelofibrosis and Essential Thrombocythemia Observational STudy (MOST) (NCT02953704) is an ongoing multicenter, noninterventional, longitudinal, prospective, observational study in patients with essential thrombocythemia (ET) or myelo
Autor:
Srdan Verstovsek, Haobo Ren, Michael R. Grunwald, Patricia Kalafut, Robyn M. Scherber, Ivy Altomare
Publikováno v:
Blood. 136:12-13
Background: Essential thrombocythemia (ET) is a chronic myeloproliferative neoplasm (MPN) characterized by thrombocytosis and increased risk of thrombotic events and hemorrhage. Treatment of ET is risk-adapted, focused on preventing thrombosis, bleed
Autor:
Robyn M. Scherber, Patricia Kalafut, Ruben A. Mesa, Haobo Ren, Ellen K. Ritchie, Craig M. Kessler
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 20:S327
Context: MF is a chronic myeloproliferative neoplasm (MPN) that can be accompanied by substantial symptom burden, diminished quality-of-life (QoL), and reduced survival. Objective: To report PROs in patients with lower-risk MF at time of enrollment i
Autor:
Philomena Colucci, Srdan Verstovsek, Patricia Kalafut, Dilan Paranagama, Aaron T. Gerds, Roger M. Lyons
Publikováno v:
Blood. 134:4190-4190
Introduction: Myelofibrosis (MF) is a chronic Philadelphia chromosome-negative myeloproliferative neoplasm characterized by progressive bone marrow (BM) fibrosis, extramedullary hematopoiesis, splenomegaly, constitutional symptoms, and shortened surv
Autor:
Anas Al-Janadi, Ellen K. Ritchie, Patricia Kalafut, Philomena Colucci, Dilan Paranagama, Ruben A. Mesa
Publikováno v:
Blood. 134:1665-1665
Introduction: ET is a chronic myeloproliferative neoplasm (MPN) characterized by thrombocytosis and an increased risk for thrombotic and hemorrhagic events. ET can be associated with substantial symptom burden, impaired quality of life (QoL), and red